Stockreport

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics, Inc.  (LRMR) 
PDF BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing [Read more]